You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

89 Results
Guidelines and Advice
Status: Current
Apr 2020
Guidelines and Advice
Status: In-Review
ID: GL END 7-3
Version: 4
Apr 2020
Guidelines and Advice
Status: In-Review
ID: 3-22
Version: N/A
Apr 2020
Guidelines and Advice
Status: Current
ID: GL 2-30a
Version: N/A
Mar 2020
Statistical Reports
Aug 2020
Guidelines and Advice
Status: Current
ID: ES 23-2
Version: N/A
Jun 2020
Guidelines and Advice
Status: Current
ID: GL 8-10
Version: N/A
Feb 2020
Guidelines and Advice
Status: Current
ID: MOTAC-6
Version: 2
Sep 2020
Guidelines and Advice
Status: Current
ID: GL 4-18
Version: N/A
Sep 2020
Guidelines and Advice
Status: Current
ID: 7-A-2018-2
Version: N/A
Jan 2020
Guidelines and Advice
Status: In-Review
ID: RR SCT-9
Version: N/A
Jun 2020
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
  • everolimus - In combination with exemestane, for the treatment of hormone-receptor positive, HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
ODB - General Benefit
  • exemestane
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
everolimus,
exemestane
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2020

Pages